Antisense oligonucleotides targeting rage.

OA22367AActive Publication Date: 2026-11-04RAGE BIOTECH PTY LTD
0 Cites 0 Cited by

Patent Information

Application Number
OA1202600111
Authority / Receiving Office
OA · OA
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2026-11-04
Estimated Expiration
2044-10-18
Patent Text Reader

Abstract

The present invention relates to potent spliceswitching antisense oligonucleotides that modulate alternative splicing of pre-mRNA coding for the Receptor for Advanced Glycation Endproducts (RAGE) or part thereof, and methods of treatment of RAGE-related disorders using said antisense oligonucleotides. In one aspect, the present invention provides an antisense oligonucleotide (AON) consisting of the nucleotide sequence TGCCGCCTTTGCCACAAG (5'-3'; SEQ ID NO: 1); or GCCGCCTTTGCCACAAGA (5'-3'; SEQ ID NO: 2), preferably wherein the antisense oligonucleotide comprises at least one modified nucleotide.
Need to check novelty before this filing date? Find Prior Art